Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: A placebo controlled double-blind multicentre study
Autore:
Grant, PR; Black, A; Garcia, N; Prieto, J; Garson, JA;
Indirizzi:
Royal Free & Univ Coll Med Sch, Dept Virol, London W1P 6DB, England Royal Free & Univ Coll Med Sch London England W1P 6DB n W1P 6DB, England Univ Navarra Clin, Med Interna Serv, Navarra, Spain Univ Navarra Clin Navarra Spain Clin, Med Interna Serv, Navarra, Spain
Titolo Testata:
JOURNAL OF MEDICAL VIROLOGY
fascicolo: 4, volume: 61, anno: 2000,
pagine: 439 - 442
SICI:
0146-6615(200008)61:4<439:CTWIPN>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLUTATHIONE; ACETYLCYSTEINE; INFECTION; ASSAY; ALFA; RNA;
Keywords:
hepatitis C virus; treatment; interferon; N-acetyl cysteine; clinical trial;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Garson, JA Royal Free & Univ Coll Med Sch, Dept Virol, Windeyer Bldg 46,Cleveland St,London W1P 6DB, England Royal Free & Univ Coll Med Sch Windeyer Bldg 46,Cleveland St London England W1P 6DB
Citazione:
P.R. Grant et al., "Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: A placebo controlled double-blind multicentre study", J MED VIROL, 61(4), 2000, pp. 439-442

Abstract

A small pilot study in patients with chronic hepatitis C (HCV) infection suggested that antiviral treatment with interferon (IFN) plus N-acetyl cysteine (NAC) was more effective than treatment with interferon alone [Beloqui et al. (1993) Journal of Interferon Research 13:279-282]. An attempt was made to confirm this by performing a placebo-controlled double-blind study at8 medical centres in Spain and Italy. One-hundred forty-seven patients with chronic HCV infection were investigated, 73 received 3MU IFN-alpha thriceweekly plus NAC 1800 mg daily and 74 received IFN alone. Treatment was continued for 6 months and patients were followed up for a further 6 months. Amongst patients receiving IFN plus NAC, sustained virological responses were observed in 5.5%, transient responses in 26% and non-response in 68.5%. The figures for patients receiving IFN only were 4.1%, 24.3% and 71.6% respectively. Sustained virological response was significantly associated with non-type 1 genotypes (P = 0.045) and with low pre-treatment viraemia levels (P = 0.034). Biochemical response (serum ALT concentrations) correlated with virological outcome in 97% (n = 139) of cases. Patients who experienced asustained virological response also showed reduction in the Knodell histological activity index. It is concluded that patients with chronic HCV infection are very unlikely to benefit from the addition of N-acetyl cysteine toconventional therapy with interferon-alpha. J. Med. Virol. 61: 439-442, 2000. (C) 2000 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 11:34:26